Rory M Shallis

Trials

Studies that name Rory M Shallis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05600894 · Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  National Cancer Institute (NCI) · active not recruiting · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts · principal investigator
• Ph2
  NCT03953898 · Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  National Cancer Institute (NCI) · active not recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials Consortium
  UM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026
  Named on NCT05600894, NCT03953898